OptiNose (OPTN) Stock Price, News & Analysis

Company Overview

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Key Stats

• Today's Range: $9.60 to $9.60
• 50-Day Range: $9.38 to $9.71
• 52-Week Range: $4.82 to $17.18
• Volume: N/A
• Average Volume: 63,682 shs
• Market Capitalization: $97.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

OptiNose Stock Analysis - MarketRank™

OptiNose scored higher than 17% of companies evaluated by MarketBeat, and ranked 854th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

OptiNose has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

OptiNose has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for OptiNose are expected to grow in the coming year, from ($3.22) to ($2.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OptiNose is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OptiNose is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for OPTN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OptiNose does not currently pay a dividend.

Dividend Growth

OptiNose does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -2.10

Short Interest

There is no current short interest data available for OPTN.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, OptiNose insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.30% of the stock of OptiNose is held by insiders.

Percentage Held by Institutions

85.60% of the stock of OptiNose is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OPTN Stock Analysis - Frequently Asked Questions

How were OptiNose's earnings last quarter?

OptiNose, Inc. (NASDAQ:OPTN) released its quarterly earnings data on Tuesday, May, 13th. The company reported ($1.01) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by $0.27. The firm had revenue of $18.51 million for the quarter, compared to the consensus estimate of $17.70 million.

When did OptiNose's stock split?

Shares of OptiNose reverse split on Tuesday, December 31st 2024.The 1-15 reverse split was announced on Thursday, December 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did OptiNose IPO?

OptiNose (OPTN) raised $101 million in an initial public offering on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO.

What other stocks do shareholders of OptiNose own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OptiNose investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), GE Aerospace (GE), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 8/04/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OPTN
• CIK: 1494650
• Web: www.optinose.com
• Phone: (267) 364-3500
• Fax: N/A
• Employees: 190
• Year Founded: N/A

Price Target and Rating

• Average Price Target for OptiNose: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: -6.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.48 million
• Net Margins: -41.16%
• Pretax Margin: -41.16%
• Return on Equity: N/A
• Return on Assets: -27.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.79
• Quick Ratio: 0.72

Sales & Book Value

• Annual Sales: $81.86 million
• Price / Sales: 1.19
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($11.56) per share
• Price / Book: -0.83

Miscellaneous

• Outstanding Shares: 10,127,000
• Free Float: 9,829,000
• Market Cap: $97.22 million
• Optionable: Not Optionable
• Beta: -0.88